Trial Profile
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms PRO-IMMUN
- 16 Nov 2016 Primary endpoint (Immunological response rate) has been met, according to results presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
- 16 Nov 2016 Results analysing presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
- 09 May 2015 Planned number of patients changed from 10 to 12 as reported by EU Clinical Trials Register record.